BankInvest Biomedical Venture

Description

BankInvest Biomedical Venture makes investments in research-based biotechnology companies in Europe.

Investor Profile

BankInvest Biomedical Venture has made 8 investments, with 0 in the past 12 months and 25% as lead.

Stage Focus

Series Unknown (38%)
Series C (25%)
Series B (25%)
Series D (13%)

Country Focus

United Kingdom (25%)
France (25%)
Denmark (25%)
United States (13%)
Sweden (13%)

Industry Focus

Biotechnology
Health Care
Medical
Biopharma
Pharmaceutical
Oncology
Genetics
Medical Device
Therapeutics
Manufacturing

FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does BankInvest Biomedical Venture frequently co-invest with?

Abingworth

Europe, England, United Kingdom, London

Co-Investments: 1

Credit Suisse First Boston

Europe, Zurich, Switzerland, Zurich

Co-Investments: 1

3i Plc

Co-Investments: 1

Pacific Rim Ventures

North America, California, United States, San Francisco

Co-Investments: 1

Andera Partners

Europe, Ile-de-France, France, Paris

Co-Investments: 2

Invesco

North America, Georgia, United States, Atlanta

Co-Investments: 1

Astellas Venture Management

North America, California, United States, Menlo Park

Co-Investments: 2

ODYSSEE VENTURE

Europe, Ile-de-France, France, Paris

Co-Investments: 2

Idinvest Partners

Europe, Ile-de-France, France, Paris

Co-Investments: 2

OppenheimerFunds

North America, Georgia, United States, Peachtree City

Co-Investments: 1

What are some of recent deals done by BankInvest Biomedical Venture?

F2G

Manchester, Manchester, United Kingdom

F2G discovers and develops novel drugs for the treatment of life-threatening fungal diseases.

BiotechnologyGeneticsHealth CareMedicalPharmaceutical

Series UnknownAug 18, 2008

Amount Raised: $11,753,687

Nereus Pharmaceuticals

San Diego, California, United States

Nereus Pharmaceuticals engages in the discovery and development of therapeutics for the treatment of infectious diseases and inflammation.

BiotechnologyHealth CareMedical

Series DAug 9, 2007

Amount Raised: $45,000,000

Resistentia Pharmaceuticals

Uppsala, Uppsala Lan, Sweden

Resistentia Pharmaceuticals develops immunotherapeutic products for allergic asthma and inflammatory disorders.

BiotechnologyHealth CareMedical DeviceTherapeutics

Series CSep 26, 2006

Amount Raised: $13,960,000

Cellectis

Paris, Ile-de-France, France

Cellectis is a biopharmaceutical company that develops adoptive immunotherapies for cancer.

BiopharmaBiotechnologyHealth CareMedicalOncology

Series CJun 1, 2005

Amount Raised: $6,842,352

LiPlasome Pharma

Vejle, Syddanmark, Denmark

LiPlasome, a biotech company focused on oncology, provides a liplasomal reformulation of anticancer drugs on the market.

BiotechnologyHealth CareOncologyPharmaceutical

Series BMar 1, 2005

Amount Raised: $8,010,000

Cellectis

Paris, Ile-de-France, France

Cellectis is a biopharmaceutical company that develops adoptive immunotherapies for cancer.

BiopharmaBiotechnologyHealth CareMedicalOncology

Series BMay 1, 2002

Amount Raised: $7,240,061

Oxagen

London, England, United Kingdom

Oxagen is a biopharmaceutical company developing small molecule drugs addressing asthma, and chronic allergic and inflammatory conditions.

BiopharmaBiotechnologyHealth CarePharmaceutical

Series UnknownDec 21, 2000

Amount Raised: $44,240,218

Genmab

Copenhagen, Hovedstaden, Denmark

Genmab is a biotechnology company focused on developing fully human antibody therapeutics for the potential treatment of cancer.

BiotechnologyHealth CareManufacturingMedical

Series UnknownJun 13, 2000

Amount Raised: $40,500,000

BankInvest Biomedical Venture

Description

Investor Profile

Stage Focus

Country Focus

Industry Focus

Frequently Asked Questions

Who does BankInvest Biomedical Venture frequently co-invest with?

What are some of recent deals done by BankInvest Biomedical Venture?

Ready to Raise Capital?

Pages

Free tools